These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30089413)

  • 1. Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney.
    Frazier KS; Obert LA
    Toxicol Pathol; 2018 Dec; 46(8):904-917. PubMed ID: 30089413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.
    Engelhardt JA; Fant P; Guionaud S; Henry SP; Leach MW; Louden C; Scicchitano MS; Weaver JL; Zabka TS; Frazier KS;
    Toxicol Pathol; 2015 Oct; 43(7):935-44. PubMed ID: 25717082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide.
    Frazier KS; Sobry C; Derr V; Adams MJ; Besten CD; De Kimpe S; Francis I; Gales TL; Haworth R; Maguire SR; Mirabile RC; Mullins D; Palate B; Doorten YP; Ridings JE; Scicchitano MS; Silvano J; Woodfine J
    Toxicol Pathol; 2014 Jul; 42(5):923-35. PubMed ID: 24292388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
    Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
    Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization, biomarkers, and reversibility of a monoclonal antibody-induced immune complex disease in cynomolgus monkeys (Macaca fascicularis).
    Heyen JR; Rojko J; Evans M; Brown TP; Bobrowski WF; Vitsky A; Dalton S; Tripathi N; Bollini SS; Johnson T; Lin JC; Khan N; Han B
    Toxicol Pathol; 2014 Jun; 42(4):765-73. PubMed ID: 24616262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
    Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Immune Complex Disease in Preclinical Safety Studies.
    Vahle JL
    Toxicol Pathol; 2018 Dec; 46(8):1013-1019. PubMed ID: 30157708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.
    Frazier KS
    Toxicol Pathol; 2015 Jan; 43(1):78-89. PubMed ID: 25385330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
    Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
    Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans.
    Husar E; Solonets M; Kuhlmann O; Schick E; Piper-Lepoutre H; Singer T; Tyagi G
    Toxicol Pathol; 2017 Jul; 45(5):676-686. PubMed ID: 28830332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies.
    Frazier KS
    Toxicol Pathol; 2022 Jun; 50(4):408-414. PubMed ID: 35608030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies.
    Kronenberg S; Husar E; Schubert C; Freichel C; Emrich T; Lechmann M; Giusti AM; Regenass F
    Regul Toxicol Pharmacol; 2017 Aug; 88():125-137. PubMed ID: 28624430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathogenetic role of free-circulating antibody in autologous immune complex glomerulonephritis.
    Fleuren GJ; Grond J; Hoedemaeker PJ
    Clin Exp Immunol; 1980 Aug; 41(2):205-17. PubMed ID: 6449334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antigen size and charge in immune complex glomerulonephritis.
    Isaacs KL; Miller F
    Lab Invest; 1982 Aug; 47(2):198-205. PubMed ID: 6180247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Complex-Mediated Proliferative Glomerulonephritis Induced by Paclitaxel Treatment.
    Siddiqui B; Greka A; Popovtzer M; Rennke HG; Jeselsohn R
    J Oncol Pract; 2016 Dec; 12(12):1272-1274. PubMed ID: 27845869
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of immune-deposit formation and the mediation of immune renal injury.
    Nangaku M; Couser WG
    Clin Exp Nephrol; 2005 Sep; 9(3):183-91. PubMed ID: 16189625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring immune-complex glomerulonephritis in monkeys (Macaca irus). I. Light, immunofluorescence and electron microscopic studies.
    Poskitt TR; Fortwengler HP; Bobrow JC; Roth GJ
    Am J Pathol; 1974 Jul; 76(1):145-64. PubMed ID: 4276331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.